Caroline Mburu, John Ojal, Rose Selim, Rose Ombati, Donald Akech, Boniface Karia, James Tuju, Antipa Sigilai, Gaby Smits, Pieter van Gageldonk, Fiona van der Klis, Eunice Kagucia, Anthony Scott, Ifedayo Adetifa, Stefan Flasche
{"title":"模拟感染、常规疫苗接种和补充免疫活动对肯尼亚儿童麻疹血清转化的相对贡献。","authors":"Caroline Mburu, John Ojal, Rose Selim, Rose Ombati, Donald Akech, Boniface Karia, James Tuju, Antipa Sigilai, Gaby Smits, Pieter van Gageldonk, Fiona van der Klis, Eunice Kagucia, Anthony Scott, Ifedayo Adetifa, Stefan Flasche","doi":"10.1371/journal.pcbi.1013531","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Measles outbreaks continue to cause a large burden of disease in Africa including Kenya. We used information from regular serological surveys in Kilifi Health and Demographic Surveillance System (KHDSS) in combination with mathematical modelling to estimate the relative contribution of the vaccination programme to current measles immunity.</p><p><strong>Methods: </strong>We developed a static birth cohort model to track the proportion of children who are either measles naïve or seroconverted due to natural infection or vaccination through first dose of measles-containing vaccine (MCV1), the second dose (MCV2), or supplementary immunisation activities (SIAs). We fitted the model to biennial paediatric serological survey and case notification data and used vaccination coverage estimates from the KHDSS to estimate the relative contributions of vaccination and infection to measles immunity in Kilifi.</p><p><strong>Results: </strong>We estimated that between 2009 and 2021, 60% (95%CI 55-64%) of measles seroconversion in Kilifi was attributable to MCV1, with MCV2 contributing 1.0% (95%CI 0.9-1.1%) since its introduction. Natural infection and SIAs accounted for 24% (95%CI 17-31%) and 16% (95%CI 14-19%), respectively. A hypothetical 10% increase in MCV1 coverage increased the seroconversion attributed to MCV1 to 67% (95%CI 63-71%), with concurrent reductions in seroconversion from natural infection and SIAs to 13% (95%CI 9-18%) and 10% (95%CI 9-12%), respectively. Importantly, this same 10% increase in MCV1, if administered promptly at 9 months, could potentially reduce seroconversion from natural infection further from 24% to 11% (95%CI 07-15%) and reliance on SIAs from 16% to 8% (95% CI 7-10%).</p><p><strong>Conclusion: </strong>Optimizing routine coverage timing and uptake is crucial for reducing SIAs dependence and measles susceptibility. A 10% MCV1 coverage increase could have halved susceptibility and lessened SIA demand, highlighting the potential of minor improvements in coverage to alleviate measles and reduce costly SIAs.</p>","PeriodicalId":20241,"journal":{"name":"PLoS Computational Biology","volume":"21 9","pages":"e1013531"},"PeriodicalIF":3.6000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12469164/pdf/","citationCount":"0","resultStr":"{\"title\":\"Modelling the relative contribution of infection, routine vaccination and supplementary immunisation activities to measles seroconversion in Kenyan Children.\",\"authors\":\"Caroline Mburu, John Ojal, Rose Selim, Rose Ombati, Donald Akech, Boniface Karia, James Tuju, Antipa Sigilai, Gaby Smits, Pieter van Gageldonk, Fiona van der Klis, Eunice Kagucia, Anthony Scott, Ifedayo Adetifa, Stefan Flasche\",\"doi\":\"10.1371/journal.pcbi.1013531\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Measles outbreaks continue to cause a large burden of disease in Africa including Kenya. We used information from regular serological surveys in Kilifi Health and Demographic Surveillance System (KHDSS) in combination with mathematical modelling to estimate the relative contribution of the vaccination programme to current measles immunity.</p><p><strong>Methods: </strong>We developed a static birth cohort model to track the proportion of children who are either measles naïve or seroconverted due to natural infection or vaccination through first dose of measles-containing vaccine (MCV1), the second dose (MCV2), or supplementary immunisation activities (SIAs). We fitted the model to biennial paediatric serological survey and case notification data and used vaccination coverage estimates from the KHDSS to estimate the relative contributions of vaccination and infection to measles immunity in Kilifi.</p><p><strong>Results: </strong>We estimated that between 2009 and 2021, 60% (95%CI 55-64%) of measles seroconversion in Kilifi was attributable to MCV1, with MCV2 contributing 1.0% (95%CI 0.9-1.1%) since its introduction. Natural infection and SIAs accounted for 24% (95%CI 17-31%) and 16% (95%CI 14-19%), respectively. A hypothetical 10% increase in MCV1 coverage increased the seroconversion attributed to MCV1 to 67% (95%CI 63-71%), with concurrent reductions in seroconversion from natural infection and SIAs to 13% (95%CI 9-18%) and 10% (95%CI 9-12%), respectively. Importantly, this same 10% increase in MCV1, if administered promptly at 9 months, could potentially reduce seroconversion from natural infection further from 24% to 11% (95%CI 07-15%) and reliance on SIAs from 16% to 8% (95% CI 7-10%).</p><p><strong>Conclusion: </strong>Optimizing routine coverage timing and uptake is crucial for reducing SIAs dependence and measles susceptibility. A 10% MCV1 coverage increase could have halved susceptibility and lessened SIA demand, highlighting the potential of minor improvements in coverage to alleviate measles and reduce costly SIAs.</p>\",\"PeriodicalId\":20241,\"journal\":{\"name\":\"PLoS Computational Biology\",\"volume\":\"21 9\",\"pages\":\"e1013531\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-09-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12469164/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PLoS Computational Biology\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1371/journal.pcbi.1013531\",\"RegionNum\":2,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMICAL RESEARCH METHODS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PLoS Computational Biology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1371/journal.pcbi.1013531","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
Modelling the relative contribution of infection, routine vaccination and supplementary immunisation activities to measles seroconversion in Kenyan Children.
Background: Measles outbreaks continue to cause a large burden of disease in Africa including Kenya. We used information from regular serological surveys in Kilifi Health and Demographic Surveillance System (KHDSS) in combination with mathematical modelling to estimate the relative contribution of the vaccination programme to current measles immunity.
Methods: We developed a static birth cohort model to track the proportion of children who are either measles naïve or seroconverted due to natural infection or vaccination through first dose of measles-containing vaccine (MCV1), the second dose (MCV2), or supplementary immunisation activities (SIAs). We fitted the model to biennial paediatric serological survey and case notification data and used vaccination coverage estimates from the KHDSS to estimate the relative contributions of vaccination and infection to measles immunity in Kilifi.
Results: We estimated that between 2009 and 2021, 60% (95%CI 55-64%) of measles seroconversion in Kilifi was attributable to MCV1, with MCV2 contributing 1.0% (95%CI 0.9-1.1%) since its introduction. Natural infection and SIAs accounted for 24% (95%CI 17-31%) and 16% (95%CI 14-19%), respectively. A hypothetical 10% increase in MCV1 coverage increased the seroconversion attributed to MCV1 to 67% (95%CI 63-71%), with concurrent reductions in seroconversion from natural infection and SIAs to 13% (95%CI 9-18%) and 10% (95%CI 9-12%), respectively. Importantly, this same 10% increase in MCV1, if administered promptly at 9 months, could potentially reduce seroconversion from natural infection further from 24% to 11% (95%CI 07-15%) and reliance on SIAs from 16% to 8% (95% CI 7-10%).
Conclusion: Optimizing routine coverage timing and uptake is crucial for reducing SIAs dependence and measles susceptibility. A 10% MCV1 coverage increase could have halved susceptibility and lessened SIA demand, highlighting the potential of minor improvements in coverage to alleviate measles and reduce costly SIAs.
期刊介绍：
PLOS Computational Biology features works of exceptional significance that further our understanding of living systems at all scales—from molecules and cells, to patient populations and ecosystems—through the application of computational methods. Readers include life and computational scientists, who can take the important findings presented here to the next level of discovery.
Research articles must be declared as belonging to a relevant section. More information about the sections can be found in the submission guidelines.
Research articles should model aspects of biological systems, demonstrate both methodological and scientific novelty, and provide profound new biological insights.
Generally, reliability and significance of biological discovery through computation should be validated and enriched by experimental studies. Inclusion of experimental validation is not required for publication, but should be referenced where possible. Inclusion of experimental validation of a modest biological discovery through computation does not render a manuscript suitable for PLOS Computational Biology.
Research articles specifically designated as Methods papers should describe outstanding methods of exceptional importance that have been shown, or have the promise to provide new biological insights. The method must already be widely adopted, or have the promise of wide adoption by a broad community of users. Enhancements to existing published methods will only be considered if those enhancements bring exceptional new capabilities.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
